142 related articles for article (PubMed ID: 29785614)
1. Cascade of care and factors associated with virological suppression among HIV-positive persons linked to care in the Test and Keep in Care (TAK) project.
Kowalska JD; Ankiersztejn-Bartczak M; Shepherd L; Mocroft A
Infection; 2018 Aug; 46(4):533-540. PubMed ID: 29785614
[TBL] [Abstract][Full Text] [Related]
2. Poor Linkage to Care Despite Significant Improvement in Access to Early cART in Central Poland - Data from Test and Keep in Care (TAK) Project.
Kowalska JD; Shepherd L; Ankiersztejn-Bartczak M; Cybula A; Czeszko-Paprocka H; Firląg-Burkacka E; Mocroft A; Horban A
PLoS One; 2016; 11(10):e0162739. PubMed ID: 27711159
[TBL] [Abstract][Full Text] [Related]
3. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
[TBL] [Abstract][Full Text] [Related]
4. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
[TBL] [Abstract][Full Text] [Related]
5. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
Armenia D; Di Carlo D; Cozzi-Lepri A; Calcagno A; Borghi V; Gori C; Bertoli A; Gennari W; Bellagamba R; Castagna A; Latini A; Pinnetti C; Cicalini S; Saracino A; Lapadula G; Rusconi S; Castelli F; Di Giambenedetto S; Andreoni M; Di Perri G; Antinori A; Mussini C; Ceccherini-Silberstein F; Monforte AD; Perno CF; Santoro MM;
Antivir Ther; 2019; 24(5):321-331. PubMed ID: 30977466
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD).
Templeton DJ; Wright ST; McManus H; Lawrence C; Russell DB; Law MG; Petoumenos K;
BMC Infect Dis; 2015 Aug; 15():326. PubMed ID: 26265164
[TBL] [Abstract][Full Text] [Related]
7. A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada.
Benoit AC; Younger J; Beaver K; Jackson R; Loutfy M; Masching R; Nobis T; Nowgesic E; O'Brien-Teengs D; Whitebird W; Zoccole A; Hull M; Jaworsky D; Rachlis A; Rourke S; Burchell AN; Cooper C; Hogg R; Klein MB; Machouf N; Montaner J; Tsoukas C; Raboud J; ;
Antivir Ther; 2017; 22(4):325-335. PubMed ID: 27925609
[TBL] [Abstract][Full Text] [Related]
8. Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial.
Labhardt ND; Ringera I; Lejone TI; Klimkait T; Muhairwe J; Amstutz A; Glass TR
JAMA; 2018 Mar; 319(11):1103-1112. PubMed ID: 29509839
[TBL] [Abstract][Full Text] [Related]
9. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
10. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.
Santoro MM; Di Carlo D; Armenia D; Zaccarelli M; Pinnetti C; Colafigli M; Prati F; Boschi A; Antoni AMD; Lagi F; Sighinolfi L; Gervasoni C; Andreoni M; Antinori A; Mussini C; Perno CF; Borghi V; Sterrantino G
Antivir Ther; 2018; 23(3):249-257. PubMed ID: 28935850
[TBL] [Abstract][Full Text] [Related]
11. HLA B*5701 status, disease progression, and response to antiretroviral therapy.
UK Collaborative HIV Cohort Study Steering Committee
AIDS; 2013 Oct; 27(16):2587-92. PubMed ID: 23921616
[TBL] [Abstract][Full Text] [Related]
12. Does gender or mode of HIV acquisition affect virological response to modern antiretroviral therapy (ART)?
Saunders P; Goodman AL; Smith CJ; Marshall N; O'Connor JL; Lampe FC; Johnson MA
HIV Med; 2016 Jan; 17(1):18-27. PubMed ID: 26140659
[TBL] [Abstract][Full Text] [Related]
13. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
[TBL] [Abstract][Full Text] [Related]
14. Healthcare facility characteristics associated with achievement and maintenance of HIV viral suppression among persons newly diagnosed with HIV in New York City.
Wiewel EW; Borrell LN; Jones HE; Maroko AR; Torian LV
AIDS Care; 2019 Dec; 31(12):1484-1493. PubMed ID: 30909714
[TBL] [Abstract][Full Text] [Related]
15. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
[TBL] [Abstract][Full Text] [Related]
16. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
17. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
18. Healthcare and treatment experiences among people diagnosed with HIV before and after a province-wide treatment as prevention initiative in British Columbia, Canada.
Tattersall T; Tam C; Moore D; Wesseling T; Grieve S; Wang L; Bacani N; Montaner JSG; Hogg RS; Barrios R; Salters K
BMC Public Health; 2022 May; 22(1):1022. PubMed ID: 35597938
[TBL] [Abstract][Full Text] [Related]
19. High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012.
Agolory SG; Auld AF; Odafe S; Shiraishi RW; Dokubo EK; Swaminathan M; Dalhatu I; Onotu D; Abiri O; Debem H; Bashorun A; Ellerbrock TV
PLoS One; 2017; 12(9):e0183823. PubMed ID: 28863160
[TBL] [Abstract][Full Text] [Related]
20. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
